Publications by authors named "Gary Peters"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,056

Total Likes

60

Extended Reach

64,217

Social Features

27
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.
Isabel Reinecke, Alexander Solms, Stefan Willmann, Theodore E Spiro, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E Spiro, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
Liping Zhang, Xiaoyu Yan, Keith A A Fox, Stefan Willmann, Partha Nandy, Gary Peters

J Thromb Thrombolysis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.
Jeffrey I Weitz, Annelise Segers, Gary Raskob, Robin S Roberts, Charles Francis, Gary Peters

J Thromb Haemost· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
Robert G Hart, Roland C Veltkamp, Patrick Sheridan, Mukul Sharma, Scott E Kasner, Gary Peters

J Stroke Cerebrovasc Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A A Fox, Gary Peters

Ther Adv Cardiovasc Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis.
Simon J Wilson, Thomas M Connolly, Gary Peters, Atalanta Ghosh, Maureen Johnson

Cardiovasc Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Stefan Willmann, Liping Zhang, Hannah Mayer, Hans-Ulrich Siegmund, Takahiko Tanigawa, Gary Peters

Blood Adv· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.
Scott E Kasner, Pablo Lavados, Mukul Sharma, Yongjun Wang, Yilong Wang, Gary Peters

J Stroke Cerebrovasc Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies.
Liping Zhang, Gary Peters, Lloyd Haskell, Purve Patel, Partha Nandy

J Clin Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Robert G Hart, Mukul Sharma, Hardi Mundl, Ashkan Shoamanesh, Scott E Kasner, Gary Peters

Eur Stroke J· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits and Challenges of Teaching Nursing Online: Exploring Perspectives of Different Stakeholders.
Nancy P Wingo, Gary B Peters, Nataliya V Ivankova, D Keith Gurley

J Nurs Educ· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Gary E Raskob, Alex C Spyropoulos, Julie Zrubek, Walter Ageno, Gregory Albers, Gary Peters

Thromb Haemost· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Single Intravenous Doses of JNJ-54452840, an Anti-β1-Adrenergic Receptor Antibody Cyclopeptide, in Healthy Male Japanese and Caucasian Participants.
Ivo P Nnane, Alexei H Plotnikov, Gary Peters, Maureen Johnson, Clare Kojak

Clin Pharmacokinet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Vincent Meininger, Pierre-François Pradat, Andrea Corse, Safa Al-Sarraj, Benjamin Rix Brooks, Gary Peters

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?
Elizabeth Tranter, Gary Peters, Malcolm Boyce, Steve Warrington

Br J Clin Pharmacol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Troy C Sarich, Gary Peters, Scott D Berkowitz, Frank Misselwitz, Christopher C Nessel

Ann N Y Acad Sci· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.
Pradeep J Nathan, Jeannette Watson, Jesper Lund, Ceri H Davies, Gary Peters

Int J Neuropsychopharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
Paul B Watkins, Mehul Desai, Scott D Berkowitz, Gary Peters, Yves Horsmans

Drug Saf· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
Christopher P Cannon, Steen Husted, Robert A Harrington, Benjamin M Scirica, Håkan Emanuelsson, Gary Peters

J Am Coll Cardiol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Robert F Storey, Steen Husted, Robert A Harrington, Stanley Heptinstall, Robert G Wilcox, Gary Peters

J Am Coll Cardiol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.
Simon M G Smith, Heather M Judge, Gary Peters, Martin Armstrong, Pierre Fontana

Platelets· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Steen Husted, Håkan Emanuelsson, Stan Heptinstall, Per Morten Sandset, Mark Wickens, Gary Peters

Eur Heart J· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatal septic shock associated with transfusion-transmitted Serratia marcescens.
Sandra Ramírez-Arcos, Ian Chin-Yee, Heather Hume, Margaret Fearon, Mindy Goldman, Gary Peters

Transfusion· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis